SCHEMBL6509024

SCHEMBL6509024

CCCCN1C[CH]OCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 4/20 0.41
MAPK1 P28482 2/20 0.41
HTR2A P28223 2/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.41
CHRM2 P08172 1/20 0.41
CHRM1 P11229 1/20 0.41
SCN1A P35498 1/20 0.41
HTR2B P41595 1/20 0.41
KCNH2 Q12809 1/20 0.41
SCN2A Q99250 1/20 0.41
SCN3A Q9NY46 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
USP2 O75604 1/20 0.40
LMNA P02545 1/20 0.40
DRD2 P14416 3/20 0.35
DRD3 P35462 3/20 0.35
GLB1 P16278 1/20 0.34
HTR1A P08908 1/20 0.33
DRD4 P21917 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6531561 0.94 SIGMAR1 (0.40) SIGMAR1MAPK1HTR2AALDH1A1CYP1A2
SCHEMBL151370 0.88
SCHEMBL84935 0.72 ALDH1A1 (0.61) SIGMAR1MAPK1HTR2AALDH1A1CYP1A2
SCHEMBL16877266 0.71
Hydrochloric Acid SCHEMBL25342847 0.70 MAPK1 (0.62) SIGMAR1MAPK1HTR2AALDH1A1CYP1A2
Bromide SCHEMBL27075773 0.70 ALDH1A1 (0.59) SIGMAR1MAPK1HTR2AALDH1A1CYP1A2
Ammonia Solution, Strong SCHEMBL27204552 0.70 ALDH1A1 (0.59) SIGMAR1MAPK1HTR2AALDH1A1CYP1A2
SCHEMBL1199910 0.68
Methylamine SCHEMBL28409498 0.68 KEAP1 (0.61) SIGMAR1MAPK1HTR2AALDH1A1CYP1A2
SCHEMBL3130672 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0810209-A2 Alpha - and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors G.D. SEARLE & CO. (US) 1997-12-03 EP claimed
CN-101128427-B Heterocyclic compounds as ccr2b antagonists ASTRAZENECA AB 2013-03-27 CN disclosed
CN-101128461-B Imidazo (1, 2-a) pyridine compounds as VEGF-R2 inhibitors LILLY CO ELI 2010-12-22 CN disclosed
CN-101128427-A Heterocyclic compounds as ccr2b antagonists ASTRAZENECA AB (SE) 2008-02-20 CN disclosed
CN-101128461-A Imidazo (1, 2-a) pyridine compounds as VEGF-R2 inhibitors LILLY CO ELI (US) 2008-02-20 CN disclosed
WO-2005082892-A2 TRIAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DR. REDDY'S LABORATORIES LTD. (IN) 2005-09-09 WO disclosed
EP-0958817-A1 COMPOSITION CONTAINING DIARYLALKANE DERIVATIVE AS THE ACTIVE INGREDIENT FOR TREATING OR PREVENTING PANCREATITIS SANKYO COMPANY LIMITED (JP) 1999-11-24 EP disclosed
EP-0844000-A1 Use of alpha, omega-diarylalkane derivatives in the treatment and prevention of psychosis SANKYO COMPANY LIMITED (JP) 1998-05-27 EP disclosed
EP-0810209-A2 Alpha - and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors G.D. SEARLE & CO. (US) 1997-12-03 EP disclosed
US-5556864-A TREATMENT OF CIRCULATORY DISEASES AND PSYCHOSIS SANKYO COMPANY, LIMITED (JP) 1996-09-17 US disclosed
EP-0600717-A1 Phenoxyalkylamines, -pyrrolidines and -piperidines for the treatment and prevention of circulatory diseases and psychosis SANKYO COMPANY LIMITED (JP) 1994-06-08 EP disclosed